As part of its OncView™ video series, CancerNetwork® spoke with Zofia Piotrowska, MD, an assistant professor of medicine at Harvard Medical School and a lung cancer medical oncologist at Massachusetts General Hospital, about recent data and review updates in the treatment landscape for patients with non-small-cell lung cancer and exon 20 insertions.

In the video series, Piotrowska discussed the following:

·      Overview of Advanced NSCLC with EGFR Mutations Including Exon 20 Insertions

·      Testing for the EGFR Exon 20 Insertion

·      Historical Treatment Approach for EGFR Exon 20 Insertions in NSCLC

·      Amivantamab for the Treatment of EGFR Exon 20 Insertions in NSCLC

·      Mobocertinib for the Treatment of EGFR Exon 20 Insertions in NSCLC

·      Treatment Selection for Patients With EGFR Exon 20 Insertions in NSCLC

·      Unmet Needs and Future Directions

To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.